AZNCF News and Press, AstraZeneca Plc From 09/30/20

PFE/BNTX have increased enrolment in their late-stage study of BNT162b2, leading many to speculate as to why. MRNA has not increased enrolment but slowed enrolment to focus on diversity. AZN has fallen behind a little in the US. For further details see: COVID-19 Vaccine ...

Immunome has filed proposed terms for a $30 million IPO. The firm is advancing antibody-based treatment candidates for cancer and the Covid-19 virus. IMNM is still at a preclinical stage of development, so the IPO is likely more suited to institutional investors. For further...

Sanofi reports positive data for pivotal lung cancer trial. AstraZeneca announces positive data for Lynparza in prostate cancer. Amgen reports encouraging data for investigational Sotorasib. For further details see: Sanofi Reports Positive Lung Cancer Data, And Other New...

Adverse event(s?) with AstraZeneca/Oxford University Phase 3 trial need more clarity for public confidence; the adverse event(s?) came after the second dose of the vaccine. It is doubtful that a safe and effective COVID-19 vaccine can be announced this year. Polls suggest that the...

Quick Take Taysha Gene Therapies ( TSHA ) has filed to raise $125 million in an IPO of its common stock, according to an S-1 registration statement . The company is developing genetic therapy treatments for various neurodegenerative diseases and other disorders. TSHA is still at a precl...

The following slide deck was published by AstraZeneca PLC in conjunction with this Read more ...

Source: abc news Vaccines take time to develop because they need to be very safe and also effective. It comes as no surprise (especially for coronavirus vaccine development) that the path to development will involve some findings that need careful consideration. Hence news that the AstraZe...

BioNTech SE ( BNTX ) and Pfizer ( PFE ), Moderna ( MRNA ), and AstraZeneca ( AZN ) and Oxford are leaders in the race for US approval of a vaccine for COVID-19. I feel PFE/BNTX is likely to be the first to report a result from a 30,000-patient US trial, the minimum size of trial the FDA has as...

AstraZeneca reports positive data for Phase III Farxiga trial AstraZeneca ( AZN ) reported that Farxiga has shown robust decline in the risk of kidney failure, cardiovascular or renal death in patients suffering from chronic kidney disease. The data from the Phase III DAPA-CKD trial show...

Prospects for treating early stage COVID-19 remain uncertain, with a host of monoclonal antibody products and Starpharma’s (OTCQX: SPHRY ) nasal SPL7013 antiviral spray vying for a role for prevention of infection and early treatment. Here I update on the latest developments with remdes...